118 related articles for article (PubMed ID: 7934957)
21. Comparison between in vivo mutagenicity and carcinogenicity in multiple organs by benzo[a]pyrene in the lacZ transgenic mouse (Muta Mouse).
Hakura A; Tsutsui Y; Sonoda J; Kai J; Imade T; Shimada M; Sugihara Y; Mikami T
Mutat Res; 1998 Feb; 398(1-2):123-30. PubMed ID: 9626972
[TBL] [Abstract][Full Text] [Related]
22. Sources of variability in data from a lacI transgenic mouse mutation assay.
Piegorsch WW; Lockhart AM; Margolin BH; Tindall KR; Gorelick NJ; Short JM; Carr GJ; Thompson ED; Shelby MD
Environ Mol Mutagen; 1994; 23(1):17-31. PubMed ID: 8125080
[TBL] [Abstract][Full Text] [Related]
23. Transgenic animal models for detection of in vivo mutations.
Mirsalis JC; Monforte JA; Winegar RA
Annu Rev Pharmacol Toxicol; 1995; 35():145-64. PubMed ID: 7598490
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the mutational specificity of DNA cross-linking mutagens by the Lac+ reversion assay with Escherichia coli.
Ohta T; Ohmae S; Yamaya K; Kanemichi Y; Tokishita S; Yamagata H
Teratog Carcinog Mutagen; 2001; 21(4):275-82. PubMed ID: 11406833
[TBL] [Abstract][Full Text] [Related]
25. Comparison of lacI and lacZ transgenic mouse mutation assays: an EU-sponsored interlaboratory study.
Tinwell H; Liegibel U; Krebs O; Schmezer P; Favor J; Ashby J
Mutat Res; 1995 Oct; 335(2):185-90. PubMed ID: 7477049
[TBL] [Abstract][Full Text] [Related]
26. Lack of mutagenicity of levofloxacin in lacZ transgenic mice.
Itoh S; Miura M; Shimada H
Mutagenesis; 1998 Jan; 13(1):51-5. PubMed ID: 9491394
[TBL] [Abstract][Full Text] [Related]
27. A test for neutrality of mutations of the lacZ transgene.
Cosentino L; Heddle JA
Environ Mol Mutagen; 1996; 28(4):313-6. PubMed ID: 8991058
[TBL] [Abstract][Full Text] [Related]
28. Detection of gentoxicity of benzidine and its derivatives with the Escherichia coli DJ 702 lacZ reversion mutagenicity assay.
Chen SC; Lin CS; Liang SH; Chuang JY
Lett Appl Microbiol; 2006 Jul; 43(1):22-6. PubMed ID: 16834716
[TBL] [Abstract][Full Text] [Related]
29. Analysis of 2-amino-N6-hydroxyadenine-induced mutagenesis in phage M13mp2.
Tsuchiyama H; Atsumi G; Matsuda A; Negishi K; Hayatsu H
Mutat Res; 1991 Aug; 253(1):47-54. PubMed ID: 1870609
[TBL] [Abstract][Full Text] [Related]
30. Formation and persistence of O6-ethylguanine in genomic and transgene DNA in liver and brain of lambda(lacZ) transgenic mice treated with N-ethyl-N-nitrosourea.
Mientjes EJ; Hochleitner K; Luiten-Schuite A; van Delft JH; Thomale J; Berends F; Rajewsky MF; Lohman PH; Baan RA
Carcinogenesis; 1996 Nov; 17(11):2449-54. PubMed ID: 8968062
[TBL] [Abstract][Full Text] [Related]
31. Evidence for in vivo non-mutagenicity of the carcinogen hydrazine sulfate in target tissues of lacZ transgenic mice.
Douglas GR; Gingerich JD; Soper LM
Carcinogenesis; 1995 Apr; 16(4):801-4. PubMed ID: 7728958
[TBL] [Abstract][Full Text] [Related]
32. LacZ transgenic mouse models: their application in genetic toxicology.
Gossen JA; de Leeuw WJ; Vijg J
Mutat Res; 1994 Jun; 307(2):451-9. PubMed ID: 7514719
[TBL] [Abstract][Full Text] [Related]
33. Sources of variability in data from a positive selection lacZ transgenic mouse mutation assay: an interlaboratory study.
Piegorsch WW; Lockhart AC; Carr GJ; Margolin BH; Brooks T; Douglas GR; Liegibel UM; Suzuki T; Thybaud V; van Delft JH; Gorelick NJ
Mutat Res; 1997 Feb; 388(2-3):249-89. PubMed ID: 9057887
[TBL] [Abstract][Full Text] [Related]
34. Differential in vivo mutagenicity of the carcinogen/non-carcinogen pair 2,4- and 2,6-diaminotoluene.
Hayward JJ; Shane BS; Tindall KR; Cunningham ML
Carcinogenesis; 1995 Oct; 16(10):2429-33. PubMed ID: 7586147
[TBL] [Abstract][Full Text] [Related]
35. N-Nitrosodi-n-propylamine induces organ specific mutagenesis with specific expression times in lacZ transgenic mice.
Itoh S; Miura M; Itoh T; Miyauchi Y; Suga M; Takahashi Y; Kasahara Y; Yamamura E; Hirono H; Shimada H
Mutat Res; 1999 Aug; 444(2):309-19. PubMed ID: 10521671
[TBL] [Abstract][Full Text] [Related]
36. The use of transgenic mice for short-term, in vivo mutagenicity testing.
Kohler SW; Provost GS; Kretz PL; Fieck A; Sorge JA; Short JM
Genet Anal Tech Appl; 1990 Dec; 7(8):212-8. PubMed ID: 2151115
[TBL] [Abstract][Full Text] [Related]
37. Development of new tester strains derived from E. coli WP2uvrA for the determination of mutational specificity.
Ohta T; Watanabe-Akanuma M; Tokishita S; Shiga Y; Yamagata H
Mutat Res; 1998 Mar; 413(3):219-25. PubMed ID: 9651533
[TBL] [Abstract][Full Text] [Related]
38. In vivo mutagenicity and hepatocarcinogenicity of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in bitransgenic c-myc/lambda lacZ mice.
Ryu DY; Pratt VS; Davis CD; Schut HA; Snyderwine EG
Cancer Res; 1999 Jun; 59(11):2587-92. PubMed ID: 10363978
[TBL] [Abstract][Full Text] [Related]
39. Statistical analysis of lacZ mutant frequency data from MutaMouse mutagenicity assays.
Fung KY; Douglas GR; Krewski D
Mutagenesis; 1998 May; 13(3):249-55. PubMed ID: 9643583
[TBL] [Abstract][Full Text] [Related]
40. Mutant frequencies in lacZ transgenic mice following the internal irradiation from 89Sr or the external gamma-ray irradiation.
Takahashi S; Kubota Y; Sato H
J Radiat Res; 1998 Mar; 39(1):53-60. PubMed ID: 9610032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
